- Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug<figure><div><img src="https://imgproxy.divecdn.com/NkRGM2WlVG_bih055HG7zy8PbwZNjna8pIs5Yzt_9MI/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTcwOTEzMjEwLmpwZ…BioPharma Dive · 1mo ago↗ source
- STAT+: Radiopharmaceutical shows promise in post-Pluvicto settingAbivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The ReadoutSTAT · 1mo ago↗ source
- STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and moreLilly gave hospitals participating in a federal drug discount program five days to submit claims data or it will stop the price breaks